Vantage logo

Medtech takes on pain

Attempts to treat pain with non-opioid drugs have ended in repeated failures – but device makers have met with greater success.

Vantage logo

Cytokine players keep the faith

The demise of Nektar’s bempegaldesleukin has not stemmed the tidal wave of companies developing IL-2 and IL-15 therapies.